© 2021 MJH Life Sciences and Patient Care Online. All rights reserved.
© 2021 MJH Life Sciences™ and Patient Care Online. All rights reserved.
September 11, 2013
Incretin drugs, which offer ease of use, very little hypoglycemia, and no weight gain (or even weight loss) seem to be an ideal therapy. But 80% to 90% of patients don’t stay on them. Why not?
August 03, 2013
Incretin-based T2DM therapy is not a direct cause of pancreatitis or pancreatic cancer asserts the European Medicines Agency.
July 26, 2013
GLP-1 receptor antagonists suppress post-meal glucose excursions and are compatible with basal insulin; the combination addresses both FPG and PPG.
June 26, 2013
Bariatric surgery is recommended along with oral therapy to help patients with type 2 diabetes control overweight and obesity.
June 25, 2013
Sodium-glucose linked transporter 2 inhibitors lower renal threshold for glucose transport, cause glycosuria, improved glycemic control, weight loss.
Initial triple-agent therapy for type 2 diabetes, compared with step-wise add-on therapy, produced a durable drop in A1C.
Combination therapy that addresses both fasting and post-meal glucose elevation is the next big thing in T2DM management.
June 24, 2013
Obesity and kidney disease need to be aggressively managed in patients with type 2 diabetes mellitus.
May 23, 2013
Betatrophin, a naturally occurring hormone, may help restore beta cell mass, and so insulin production, lost through the pathologic changes of the diabetic process.
August 28, 2012
Early use of combination therapy to treat type 2 diabetes is shown to limit glucose toxicity and preserve beta-cell function.